- active not recruitingPHASE2
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
This study looks at a medicine called trametinib for children and young people (aged 1 month to 25 years) with certain brain tumours or nerve tumours that haven't responded to other treatments. It aims to see how well the medicine works and understand more about these conditions.
Canada - recruiting
Monitoring of Patients With Low-grade Gliomas Using Circulating miRNA
This study looks at using tiny molecules called microRNAs from blood samples to find out if glioma brain tumours are coming back earlier. This could help doctors treat Grade 2 and 3 brain tumours sooner, giving patients better care.
France - active not recruitingPHASE3
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
This study is for children and young people under 25 with a type of brain tumour called low-grade glioma. It compares a new medicine, tovorafenib, with standard chemotherapy to see which works best and is safest for those needing first-time treatment.
United States · Australia · Austria - recruitingPHASE2
Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma
This study looks at a new way to plan radiation treatment for low-grade glioma, a type of brain tumour. It aims to see if using a special computer model can help reduce side effects after treatment by making the plan more precise.
Germany - recruitingEARLY_PHASE1
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
This study looks at a new combination of two medicines, tovorafenib and vinblastine, for children and young adults (up to 25) with a type of brain tumour called low-grade glioma. It focuses on tumours with specific genetic changes.
Canada - recruitingPHASE2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
This study is looking into a new medicine, Tovorafenib, for children and young adults aged 6 months to 25 years in the UK. It focuses on those with specific types of brain tumours (low-grade glioma) or advanced solid tumours that have come back or gotten worse, especially if they have certain genetic changes.
United States · Australia · Canada - active not recruitingPHASE3
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
This study compares a new drug, selumetinib, with a standard treatment (carboplatin/vincristine) for children and young people aged 2-21 with a type of brain tumour called low-grade glioma, linked to Neurofibromatosis Type 1. It aims to see if the new drug is as effective and especially if it improves vision.
United States · Canada · Puerto Rico